Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S

INTRODUCTION: EGFR G724S has been described to mediate resistance to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs). In vitro experiments have provided compelling evidence that G724S retains sensitivity for afatinib. Nevertheless, limited data have reported the clinical efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yang, Jiang, Benyuan, Liu, Shulin, Zhang, Zhonghan, Fang, Wenfeng, Yang, Yunpeng, Li, Xin, Zhao, Jingyi, Zhao, Hongyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474270/
https://www.ncbi.nlm.nih.gov/pubmed/34590038
http://dx.doi.org/10.1016/j.jtocrr.2021.100193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474270/
https://www.ncbi.nlm.nih.gov/pubmed/34590038
http://dx.doi.org/10.1016/j.jtocrr.2021.100193

Ejemplares similares